{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T05:32:54Z","timestamp":1702445574299},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s11596-021-2387-1","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T10:03:41Z","timestamp":1629194621000},"page":"827-831","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Features of Oxaliplatin-induced Hypersensitivity Reactions in Chinese Patients: A Retrospective Multicenter Analysis"],"prefix":"10.1007","volume":"41","author":[{"given":"Min","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zao-qin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu-yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"issue":"5","key":"2387_CR1","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00280-017-3294-9","volume":"79","author":"H Ohta","year":"2017","unstructured":"Ohta H, Hayashi T, Murai S, et al. Comparison between hypersensitivity reactionstocyclesofmodifiedFOLFOX6 and XELOX therapies in patients with colorectal cancer. Cancer Chemother Pharmacol, 2017,79(5):1021\u20131029","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2014","key":"2387_CR2","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00280-014-2437-5","volume":"73","author":"SY Lee","year":"2014","unstructured":"Lee SY, Kang HR, Song WJ, et al. Overcoming oxaliplatin hypersensitivity: different strategies are needed according to the severity and previous exposure. Cancer Chemother Pharmacol, 2014,73(2014):1021\u20131029","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2387_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/ecc.12156","volume":"24","author":"H Yamauchi","year":"2015","unstructured":"Yamauchi H, Goto T, Takayoshi K, et al. A retrospective analysis of the risk factors for allergic reactions induced by the administration of oxaliplatin. Eur J Cancer Care, 2015,24(1):111\u2013116","journal-title":"Eur J Cancer Care"},{"issue":"15","key":"2387_CR4","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.ejca.2005.06.021","volume":"41","author":"F Maindrault-Goebel","year":"2005","unstructured":"Maindrault-Goebel F, Andr\u00e9 T, Tournigand C, et al. Allergic-type reactions to oxaliplatin: Retrospective analysis of 42 patients. Eur J Cancer, 2005,41(15):2262\u20132267","journal-title":"Eur J Cancer"},{"issue":"6","key":"2387_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1159\/000355831","volume":"85","author":"SJ Park","year":"2013","unstructured":"Park SJ, Lee KY, Park WS, et al. Clinical Outcomes of Reintroducing Oxaliplatin to Patients with Colorectal Cancer after Mild Hypersensitivity Reactions. Oncology, 2013,85(6):323\u2013327","journal-title":"Oncology"},{"key":"2387_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2050-6511-15-1","volume":"15","author":"M Parel","year":"2014","unstructured":"Parel M, Ranchon F, Nosbaum A, et al. Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacol Toxicol, 2014,15:1","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"2387_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1179\/1973947814Y.0000000204","volume":"27","author":"F Aroldi","year":"2015","unstructured":"Aroldi F, Prochilo T, Bertocchi P, et al. Oxaliplatin-induced hypersensitivity reaction: underlying mechanisms and management. J Chemother, 2015,27(2):63\u201366","journal-title":"J Chemother"},{"issue":"1","key":"2387_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/IGC.0000000000000307","volume":"25","author":"NV Kolomeyevskaya","year":"2015","unstructured":"Kolomeyevskaya NV, Lele SB, Miller A, et al. Oxaliplatin Is a Safe Alternative Option for Patients with Recurrent Gynecologic Cancers After Hypersensitivity Reaction to Carboplatin. Int J Gynecol Cancer, 2015,25(1):42\u201348","journal-title":"Int J Gynecol Cancer"},{"issue":"2007","key":"2387_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1177\/1078155207079877","volume":"13","author":"N Kitada","year":"2007","unstructured":"Kitada N, Dan T, Takara K, et al. CASE REPORT Oxaliplatin-induced hypersensitivity reaction displaying marked elevation of immunoglobulin E. J Oncol Pharm Practice, 2007,13(2007):233\u2013235","journal-title":"J Oncol Pharm Practice"},{"issue":"2013","key":"2387_CR10","doi-asserted-by":"publisher","first-page":"445","DOI":"10.9738\/INTSURG-D-12-00020.1","volume":"98","author":"T Kobayashi","year":"2013","unstructured":"Kobayashi T, Masaki T, Kogawa K, et al. Hemoptysis and Acute Respiratory Syndrome (ARDS) as Delayed-Type Hypersensitivity After FOLFOX4 Plus Bevacizumab Treatment. Int Surg, 2013,98(2013):445\u2013449","journal-title":"Int Surg"},{"issue":"3","key":"2387_CR11","first-page":"1","volume":"12","author":"MA Bautista","year":"2010","unstructured":"Bautista MA, Bautista MA, Stevens WT, et al. Hypersensitivity reaction and acute immune mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. J Hematol Oncol, 2010, 12(3):1\u20138","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2387_CR12","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.7314\/APJCP.2016.17.4.1637","volume":"17","author":"N Bano","year":"2016","unstructured":"Bano N, Najam R, Qazi F, et al. Clinical Features of Oxaliplatin Induced Hypersensitivity Reactions and Therapeutic Approaches. Asian Pac J Cancer Prev, 2016, 17(4):1637\u20131641","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"2387_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1517\/14740338.5.5.687","volume":"5","author":"MW Saif","year":"2006","unstructured":"Saif MW. Hypersensitivity reactions associated with oxaliplatin. Expert Opion Drug Saf, 2006,5(5):687\u2013694","journal-title":"Expert Opion Drug Saf"},{"key":"2387_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000205263","volume":"76","author":"BH Kim","year":"2009","unstructured":"Kim BH, Bradley T, Tai J, et al. Hypersensitivity to Oxaliplatin: An Investigation of Incidence and Risk Factors, and Literature Review. Oncology, 2009,76:231\u2013238","journal-title":"Oncology"},{"issue":"2013","key":"2387_CR15","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/00001813-200310000-00007","volume":"14","author":"G Lenza","year":"2003","unstructured":"Lenza G, Hackera UT, Kern W, et al. Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution. Anti-Cancer Drugs, 2003,14(2013):731\u2013733","journal-title":"Anti-Cancer Drugs"},{"issue":"1","key":"2387_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000178163","volume":"76","author":"A Polyzos","year":"2008","unstructured":"Polyzos A, Tsavaris N, Gogas H, et al. Clinical Features of Hypersensitivity Reactions to Oxaliplatin: A 10-Year Experience. Oncology, 2008,76(1):36\u201341","journal-title":"Oncology"},{"key":"2387_CR17","doi-asserted-by":"publisher","first-page":"207084","DOI":"10.1155\/2010\/207084","volume":"2010","author":"N Makrilia","year":"2010","unstructured":"Makrilia N, Syrigou E, Kaklamanos I, et al. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs, 2010,2010:207084","journal-title":"Met Based Drugs"},{"issue":"6","key":"2387_CR18","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.clinthera.2008.06.007","volume":"30","author":"H Nozawa","year":"2008","unstructured":"Nozawa H, Muto Y, Yamada Y. Desensitization to Oxaliplatin with Two Stages of Premedication in a Patient with Metastatic Rectal Cancer. Clin Therap, 2008,30(6):1160\u20131165","journal-title":"Clin Therap"},{"issue":"11","key":"2387_CR19","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1517\/14740338.2014.963551","volume":"13","author":"MI Toki","year":"2014","unstructured":"Toki MI, Saif MW, Syrigos KN. Hypersensitivity reactions associated with oxaliplatin and their clinical management. Expert Opion Drug Saf, 2014,13(11):1545\u20131554","journal-title":"Expert Opion Drug Saf"},{"key":"2387_CR20","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1634\/theoncologist.9-5-546","volume":"9","author":"D Gammon","year":"2004","unstructured":"Gammon D, Bhargava P, Mccormick MJ. Hypersensitivity Reactions to Oxaliplatin and the Application of a Desensitization Protocol. Oncologist, 2004,9:546\u2013549","journal-title":"Oncologist"},{"issue":"2","key":"2387_CR21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3816\/CCC.2009.n.017","volume":"8","author":"EI Syrigou","year":"2009","unstructured":"Syrigou EI, Karapanagiotou EM, Alamara CV, et al. Hypersensitivity Reactions to Oxaliplatin: A Retrospective Study and the Development of a Desensitization Protocol. Clin Colorectal Cancer, 2009, 8(2):106\u2013109","journal-title":"Clin Colorectal Cancer"},{"key":"2387_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdj042","volume":"17","author":"SWK Siu","year":"2006","unstructured":"Siu SWK, Chan RTT, Au GKH. Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol, 2006,17:259\u2013261","journal-title":"Ann Oncol"},{"issue":"5","key":"2387_CR23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000471844","volume":"62","author":"M Waddle","year":"2017","unstructured":"Waddle M, Irvin M, Gupta E, et al. Acute Disseminated Intravascular Coagulation after Oxaliplatin Infusion. Chemotherapy, 2017,62(5):295\u2013300","journal-title":"Chemotherapy"},{"issue":"5","key":"2387_CR24","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s11096-009-9313-0","volume":"31","author":"J Lai","year":"2009","unstructured":"Lai J, Wang W. Acute hemolysis after receiving oxaliplatin treatment: a case report and literature review. Pharm World Sci, 2009,31(5):538\u2013541","journal-title":"Pharm World Sci"},{"issue":"1","key":"2387_CR25","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1177\/1430.15831","volume":"100","author":"S Garciaz","year":"2014","unstructured":"Garciaz S, Oziel-Taieb S, Dermeche S, et al. Acute immune hematological complication of oxaliplatin. A series of 3 cases. Tumori, 2014,100(1):e17\u2013e19","journal-title":"Tumori"},{"issue":"2","key":"2387_CR26","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/j.clcc.2016.11.005","volume":"16","author":"P Phull","year":"2017","unstructured":"Phull P, Quillen K, Hartshorn KL. Acute Oxaliplatin-induced Hemolytic Anemia, Thrombocytopenia, and Renal Failure: Case Report and a Literature Review. Clin Colorectal Cancer, 2017,16(2):e105\u2013e107","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"2387_CR27","first-page":"75","volume":"15","author":"I Gonz\u00e1lez-Mahave","year":"2005","unstructured":"Gonz\u00e1lez-Mahave I, Lobera Iabairu T, Blasco Sarrami\u00e1n A, et al. Anaphylaxis produced by oxaliplatin. J Investig Allergol Clin immunol, 2005,15(1):75","journal-title":"J Investig Allergol Clin immunol"},{"issue":"2008","key":"2387_CR28","first-page":"3115","volume":"28","author":"Y Shao","year":"2008","unstructured":"Shao Y, Hong R. Fatal Thrombocytopenia after Oxaliplatin-based Chemotherapy. Anticancer Res, 2008, 28(2008):3115\u20133118","journal-title":"Anticancer Res"},{"issue":"2011","key":"2387_CR29","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s10147-010-0170-6","volume":"16","author":"Y Kidera","year":"2011","unstructured":"Kidera Y, Satoh T, Ueda S, et al. High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. Int J Clin Oncol, 2011,16(2011):244\u2013249","journal-title":"Int J Clin Oncol"},{"issue":"2014","key":"2387_CR30","first-page":"537","volume":"34","author":"M Pagani","year":"2014","unstructured":"Pagani M, Bonadonna P. Skin Test Protocol for the Prevention of Hypersensitivity Reactions to Oxaliplatin. Anticancer Res, 2014,34(2014):537\u2013540","journal-title":"Anticancer Res"},{"key":"2387_CR31","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/annonc\/mdg092","volume":"14","author":"C Garufi","year":"2003","unstructured":"Garufi C, Cristaudo A, Vanni B, et al. Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol, 2003,14:497\u2013498","journal-title":"Ann Oncol"},{"issue":"1","key":"2387_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.18176\/jiaci.0119","volume":"27","author":"X Zhang","year":"2017","unstructured":"Zhang X, Zhao Y, Zheng Y, et al. The Effects of Prolonged Infusion on Reducing Oxaliplatin Hypersensitivity Reactions. J Investig Allergol Clin Immunol, 2017,27(1):65\u201366","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2387_CR33","first-page":"5521","volume":"32","author":"T Yanai","year":"2012","unstructured":"Yanai T, Iwasa S, Hashimoto H, et al. Successful Rechallenge for Oxaliplatin Hypersensitivity Reactions in Patients with Metastatic Colorectal Cancer. Anticancer Res, 2012,32:5521\u20135526","journal-title":"Anticancer Res"},{"issue":"9","key":"2387_CR34","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1097\/IGC.0000000000000295","volume":"24","author":"PG Rose","year":"2014","unstructured":"Rose PG, Metz C, Link N. Desensitization With Oxaliplatin in Patients Intolerant of Carboplatin Desensitization. Int J Gynecoll Cancer, 2014,24(9):1603\u20131606","journal-title":"Int J Gynecoll Cancer"},{"issue":"2007","key":"2387_CR35","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/01.pap.0000249924.90645.5b","volume":"14","author":"DA Edmondson","year":"2007","unstructured":"Edmondson DA, Gruling BJ, Urmanski AM, et al. Oxaliplatin Hypersensitivity: Case Report and Successful Repeat Desensitization. Am J Therapeut, 2007,14(2007):116\u2013118","journal-title":"Am J Therapeut"},{"issue":"1","key":"2387_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaip.2013.08.011","volume":"2","author":"JT Wong","year":"2013","unstructured":"Wong JT, Ling M, Patil S, et al. Oxaliplatin Hypersensitivity: Evaluation, Implications of Skin Testing, and Desensitization. J Allergy Clin Immunol Pract, 2013,2(1):40\u201345","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-021-2387-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-021-2387-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-021-2387-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T10:40:20Z","timestamp":1629196820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-021-2387-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["2387"],"URL":"https:\/\/doi.org\/10.1007\/s11596-021-2387-1","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"23 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There is no conflict of interest in the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}}]}}